Clin Osteol 2018; 23(3): 100-104

Kostné prejavy porúch štítnej žľazyReview articles

Bakos Bence1, Takács István1, Stern H. Paula2, Lakatos Péter1
1 -1st Department of Medicine, Semmelweis University, Budapest, Hungary
2 Department of Pharmacology, Northwestern University, Chicago, IL, USA

Hormóny štítnej žľazy ovplyvňujú metabolizmus, proliferáciu a diferenciáciu každej bunky v tele a kostné tkanivo nie z tohto pravidla žiadnou výnimkou. Tyroxín ovplyvňuje všetky typy kostných buniek, od osteoblastov a osteocytov až po chondrocyty a osteoklasty. Neprekvapuje preto, že rôzne narušenia funkcie štítnej žľazy môžu mať pre kostru mladistvého i zrelého človeka celý rad následkov. Niektoré z týchto porúch funkcie štítnej žľazy, ako je rezistencia na tyreoidálne hormóny (RTH), sú pomerne vzácne, zatiaľ čo iné patria medzi najzvyčajnejšie endokrinopatie ako aj u detí, tak aj u dospelých. Napríklad hypertyreóza je jednou z najčastejších príčin sekundárnej osteoporózy, pričom v posledných rokoch je aj kolísanie v normálnej funkcii štítnej žľazy spojované s rizikom zlomeniny. Pre praktikujúceho osteológa je teda nevyhnutné sa dôkladne zoznámiť so vzťahom, ktorý jestvuje medzi rôznymi ochoreniami štítnej žľazy a stavom kostí. V našom príspevku zhŕňame základne poznatky o bunkovom pôsobení tyreoidálnych hormónov, o ich úlohe pri regulácii kostného metabolizmu aj klinický význam najčastejších porúch funkcie štítnej žľazy pre každodennú prax.

Keywords: endokrinopatie; hormóny štítnej žlazy; hypertyreóza; kostný metaboizmus; sekundárna osteo­poróza; tyreopatire; tyroxín

Published: December 11, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bence B, Takács I, Paula SH, Lakatos P. Kostné prejavy porúch štítnej žľazy. Clinical Osteology. 2018;23(3):100-104.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Germain P, Staels B, Dacquet C et al. Overview of nomenclature of nuc1. Germain P, Staels B, Dacquet C et al. Overview of nomenclature of nuclear receptors. Pharmacol Rev 2006; 58(4): 685-704. Available on DOI: <http://doi:10.1124/pr.58.4.2>. Go to original source...
    2. Abu EO, Bord S, Horner A et al. The expression of thyroid hormone receptors in human bone. Bone 1997; 21(2): 137-142. Go to original source...
    3. Lakatos P, Stern PH. Evidence for direct non-genomic effects of triiodothyronine on bone rudiments in rats: stimulation of the inositol phosphate second messenger system. Acta Endocrinol (Copenh) 1991; 125(5): 603-608. Go to original source...
    4. Gouveia CHA, Miranda-Rodrigues M, Martins GM et al. Thyroid Hormone and Skeletal Development. Vitam Horm 2018; 106 : 383-472. Available on DOI: <http://doi:10.1016/bs.vh.2017.06.002>. Go to original source...
    5. Varga F, Rumpler M, Zoehrer R et al. T3 affects expression of collagen I and collagen cross-linking in bone cell cultures. Biochem Biophys Res Commun 2010; 402(2): 180-185. Available on DOI: <http://doi:10.1016/j.bbrc.2010.08.022>. Go to original source...
    6. O'Shea PJ, Bassett JH, Cheng SY et al. Characterization of skeletal phenotypes of TRalpha1 and TRbeta mutant mice: implications for tissue thyroid status and T3 target gene expression. Nucl Recept Signal 2006; 4: e011. Available on DOI: <http://doi:10.1621/nrs.04011>. Go to original source...
    7. Ma R, Morshed S, Latif R et al. The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis. Thyroid 2011; 21(8): 897-906. Available on DOI: <http://doi:10.1089/thy.2010.0457>. Go to original source...
    8. Ford G, LaFranchi SH. Screening for congenital hypothyroidism: a worldwide view of strategies. Best Pract Res Clin Endocrinol Metab 2014; 28(2): 175-187. Available on DOI: <http://doi:10.1016/j.beem.2013.05.008>. Go to original source...
    9. Polak M, Legac I, Vuillard E et al. Congenital hyperthyroidism: the fetus as a patient. Horm Res 2006; 65(5): 235-242. Available on DOI: <http://doi:10.1159/000092454>. Go to original source...
    10. Chester J, Rotenstein D, Ringkananont U et al. Congenital neonatal hyperthyroidism caused by germline mutations in the TSH receptor gene. J Pediatr Endocrinol Metab 2008; 21(5): 479-486. Go to original source...
    11. Refetoff S1, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 1999; 14(3): 348-399. Available on DOI: <http://doi:10.1210/edrv-14-3-348>.
    12. Demir K, van Gucht AL, Büyükinan M, et al. Diverse Genotypes and Phenotypes of Three Novel Thyroid Hormone Receptor-α Mutations. J Clin Endocrinol Metab 2016; 101(8): 2945-2954. Available on DOI: <http://doi.org/10.1210/jc.2016-1404>. Go to original source...
    13. Garnero P, Vassy V, Bertholin A et al. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 1994; 78(4): 955-959. Available on DOI: <http://doi:10.1210/jcem.78.4.8157727>. Go to original source...
    14. Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk -⁠ a meta-analysis. Thyroid 2003; 13(6): 585-593. Available on DOI: <http://doi:10.1089/105072503322238854>. Go to original source...
    15. El Hadidy el HM, Ghonaim M, El Gawad SSH et al. Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men. BMC Endocr Disord 2011; 11 : 15. Available on DOI: <http://doi:10.1186/1472-6823-11-15>. Go to original source...
    16. Kužma M, Vaňuga P, Binkley N et al. High serum fractalkine is associated with lower trabecular bone score in premenopausal women with Graves' disease. Horm Metab Res 2018; 50(8): 609-614. Available on DOI: <http://doi:10.1055/a-0633-2814>. Go to original source...
    17. Nagasaka S, Sugimoto H, Nakamura T et al. Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves' thyrotoxicosis. Clin Endocrinol (Oxf) 1997; 47(2): 215-221. Go to original source...
    18. Vestergaard P, Rejnmark L, Mosekilde L. Influence of hyper -⁠ and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int 2005; 77(3): 139-144. Available on DOI: <http://doi:10.1007/s00223-005-0068-x>. Go to original source...
    19. Segna D, Bauer DC, Feller M et al. Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts. Intern Med 2018; 283(1): 56-72. Available on DOI: <http://doi: doi: 10.1111/joim.12688>. Go to original source...
    20. Kim CW, Hong S, Oh SH, Lee JJ et al. Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma. J Bone Metab 2015; 22(3): 135-141. Available on DOI: <http://doi:10.11005/jbm.2015.22.3.135>. Go to original source...
    21. Waring AC, Harrison S, Fink HA et al. A prospective study of thyroid function, bone loss, and fractures in older men: The MrOS study. J Bone Miner Res 2013; 28(3): 472-479. Available on DOI: <http://doi:10.1002/jbmr.1774>. Go to original source...
    22. Garin MC, Arnold AM, Lee JS et al. Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular health study. J Clin Endocrinol Metab 2014; 99(8): 2657-2664. Available on DOI: <http://doi:10.1210/jc.2014-1051>. Go to original source...
    23. van Rijn LE, Pop VJ, Williams GR. Low bone mineral density is related to high physiological levels of free thyroxine in peri-menopausal women. Eur J Endocrinol 2014; 170(3): 461-468. Available on DOI: <http://doi:10.1530/EJE-13-0769>. Go to original source...
    24. Leader A, Ayzenfeld RH, Lishner M et al. Thyrotropin levels within the lower normal range are associated with an increased risk of hip fractures in euthyroid women, but not men, over the age of 65 years. J Clin Endocrinol Metab 2014; 99(8): 2665-2673. Available on DOI: <http://doi:10.1210/jc.2013-2474>. Go to original source...
    25. Hwangbo Y, Kim JH, Kim SW et al. High-normal free thyroxine levels are associated with low trabecular bone scores in euthyroid postmenopausal women. Osteoporos Int 2016; 27(2): 457-462. Available on DOI: <http://doi:10.1007/s00198-015-3270-3>. Go to original source...
    26. Vestergaard P, Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 2002; 12(5): 411-419. Available on DOI: <http://doi:10.1089/105072502760043503>. Go to original source...
    27. González-Rodríguez LA, Felici-Giovanini ME, Haddock L. Thyroid dysfunction in an adult female population: A population-based study of Latin American Vertebral Osteoporosis Study (LAVOS) -⁠ Puerto Rico site. P R Health Sci J 2013; 32(2): 57-62.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.